GlassScriptPhysician profile
Matthew C Haley
NPI 1851384085
$31,155.50
in general payments reported to CMS, 2019-2025
72 companies · $5,007 in 2025
The $5,007 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,807 · 2020: $3,309 · 2021: $4,336 · 2022: $5,278 · 2023: $4,527 · 2024: $4,891 · 2025: $5,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,424.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,231.36 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, General - Tachy, General - Brady |
| Novo Nordisk INC | $3,201.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,571.60 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,417.65 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,757.49 | 2019-2025 | |
| Amgen INC. | $1,679.84 | 2019-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,513.30 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $1,201.49 | 2021-2025 | |
| Daiichi Sankyo INC. | $979.04 | 2019-2023 | Injectafer |
| Lilly USA, LLC | $949.13 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $811.75 | 2019-2025 | |
| Astellas Pharma US INC | $782.97 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $774.04 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $600.30 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $585.74 | 2022-2025 | Rexulti |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Haley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.